Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Neuroendocrine Tumors 102Thyroid Neoplasms 40Thyroid Cancer, Papillary 36Carcinoid Tumor 32Neoplasms 28Multiple Endocrine Neoplasia Type 1 22Adenocarcinoma, Follicular 22Thyroid Carcinoma, Anaplastic 21Neoplasm Metastasis 21Pituitary Neoplasms 20Carcinoma, Neuroendocrine 20Pheochromocytoma 19Carcinoma, Medullary 19Paraganglioma 17Carcinoma, Non-Small-Cell Lung 17Somatostatinoma 16Adrenocortical Carcinoma 16Pancreatic Neoplasms 14Carcinoma, Islet Cell 14Insulinoma 12Glucagonoma 12Adenoma, Islet Cell 12Gastrinoma 11Colorectal Neoplasms 11Breast Neoplasms 11Sarcoma 10Melanoma 10Gastro-enteropancreatic neuroendocrine tumor 10Carcinoma, Renal Cell 10Pituitary ACTH Hypersecretion 9

Interventions

pasireotide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Growth Disorders × Endocrine × Clear all
NCT02354508 2019-12-10

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Novartis

Phase 3 Completed
123 enrolled 27 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Novartis

Phase 2 Completed
33 enrolled 24 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡